Abstract：Objective To investigate the expression level and significance of interleukin-17 (IL-17) and IL-35 in intestinal mucosa of Ulcerative colitis UC rats. Methods Six-five healthy SD male rats were divided into control group (n = 12) and experimental group (n = 53). The blank control group was not treated, and 12 SD rats were randomly selected from the experimental group for the preliminary experiment, the most appropriate dose of TNBS (2, 4, 6-trinitrobenzenesulfonic acid) modeling agent was selected to build UC animal model. Changes in body weight and general conditions (mental status, stool shape, color, etc.) were observed daily and scored according to disease activity level (DAI) since it has been formally modeled. The rest in the control group were sacrificed on day 3, day 7 and day 14, respectively. The remaining rats were formally modeled and divided into group A , group B and group C with 12 rats in each group according to the degree of ulcer (5 rats died accidently). Colonic mucosa damage index (CMDI) was used to score the colon and determine the degree of ulcer. The contents of IL-17 and IL-35 in the intestinal mucosa were detected by ELISA method, and the pathological changes of the colon were evaluated at the same time. The correlation between the levels of IL-17 and IL-35 and the degree of ulcer was obtained. Results Comparison between the experimental group and the blank group, DAI score and CMDI score were increased, and the pathological changes of colon tissue in the experimental group were significant under the microscope (P ＜ 0.05). The level of IL-17 in the intestinal mucosa of rats in each group increased significantly with the aggravation of the ulcer, and the level of IL-35 decreased significantly, with statistically significant differences (P ＜ 0.05). Conclusion During the development of ulcerative colitis, cytokines play an important role as mediators of inflammation. The content of IL-17 is positively correlated with the inflammatory response and may promote the occurrence of inflammatory response, while the content of IL-35 is negatively correlated with the degree of inflammation, and may be involved in inhibiting the occurrence and development of inflammatory response.
赵君雅 李威 李薇 孙鸿宇 李欣 官杰▲. 溃疡性结肠炎大鼠肠黏膜中IL-35与IL-17的表达及意义[J]. 中国医药导报, 2019, 16(9): 15-18.
ZHAO Junya LI Wei LI Wei SUN Hongyu Li Xin GUAN Jie▲. Expression and significance of IL-35 and IL-17 in intestinal mucosa of rats with ulcerative colitis. 中国医药导报, 2019, 16(9): 15-18.
[1] Ohkusa T，Koido S. Intestinal microbiota and ulcerative colitis [J]. J Infec Chemother，2015，21（11）：761-768.
[2] 魏永凯，李辉，李贵轲，等.溃疡性结肠炎炎症介质与免疫应答的研究[J].广州化工，2016，44（9）：10-12，18.
[3] Sventoraityte J，Zvirbliene A，Kiudelis G，et al. Immune system alterations inpatients with inflammatory bowel disease during remission [J]. Medicina（Kaunas），2008，44（1）：27-33.
[4] 修晶辉.白细胞介素35（IL-35）转基因小鼠的建立及过表达IL-35改善小鼠哮喘症状的机制研究[D].北京：北京协和医学院，2014.
[5] 董月皎.IL-35负向调控慢性乙型肝炎患者效应性T细胞的作用及其相关机制研究[D].杭州：浙江大学，2017.
[6] 廖竞.Th17细胞与儿童中性粒细胞性哮喘气道炎症相关性研究[D].南宁：广西医科大学，2014.
[7] 郑萍，牛凤丽，彭延申，等.氧化苦参碱对葡聚糖硫酸钠诱导结肠炎影响的初步研究[J].胃肠病学，2001（4）：209-210，222.
[8] Shah TA，Parikh M，Patel KV，et al. Evaluation of the effect of Punica granatum juice and punicalagin on NFκB modulation in inflammatory boweldisease [J]. Mol Cell Bioc-hem，2016，419（1/2）.
[9] 赵平，董蕾，罗金燕，等.DSS与TNBS诱导大鼠实验性结肠炎模型的对比研究[J].胃肠学，2015，20（11）：667-677.
[10] Hanauer SB. Inflammatory bowel disease：Epidemiology，pathogenesis，and therapeutic opportunities [J]. Inflamm Bowel Dis，2006，12（Suppl 1）：S3-S9.
[11] Kappelman MD，Rifas-Shiman SL，Kleinman K，et al. The prevalence and geographic distribution of Crohn′s disease and ulcerative colitis in the United States [J]. Clin Gastroenterol Hepatol，2007，5（12）：1424-14299.
[12] Herrington LJ，Liu L，Lewis JD，et al. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization，1996-2002 [J]. Am J Gastroenterol，2008，103（8）：1998-2006.
[13] Loftus CG，Lofus EV，Harmsen WS，et al. Update on the incidence and prevalence of Crohn′s disease and ulcerative colitis in Olmsted County，Minnesota，1940-2000 [J]. Inflamm Bowel Dis，2007，13（3）：254-261.
[14] 林巧嫦，廖博贤，黄飞娜.白细胞介素IL-4，IL-17在溃疡性结肠炎中的表达[J].中国医药学，2012，2（16）：44-45.
[15] 张欣，李洺，杨嫣华，等.炎症性肠病患者血清TNF-α，IL-35水平变化及其临床意义[J].内科急危重症杂志，2017，23（5）：400-402.
[16] Weaver CT，Harringt on LE，Mangan PR，et al. Thl7：an effector CD4+T cell lineage with regulatory T cell ties [J]. Immunity，2006，24（6）：677-688.
[17] Uhlig HH，Mckenzie BS，Hue S，et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology [J]. Immunity，2006；25（2）：309-318.
[18] 施沛青，朱书，钱友存.IL-17的信传导及功能研究[J].中国细胞生物学学报，2011，33（4）：345-357.
[19] Simon H，Fischer T，Almasi A，et al. Effects of mesalazine on morphological and functional changes in the indomethacininduced inflammatory bowel disease （Rat Model of Crohn′s Disease） [J]. Pathology Oncology Research Por，2016，7（2）：1-6.
[20] 郑紫丹，万晓强，刘梁英.溃疡性结肠炎患者血清IL-23和IL-17的水平变化及意义[J].细胞与分子免疫学杂志，2011，27（2）：203-204.
[21] Collison LW，Chaturvedi V，Henderson AL，et al. IL-35-mediated induction of a potent regulatory T cell population [J]. Nat Immunol，2010，11（12）：1093-1101
[22] 季明昉，孟晓弘，方一，等.炎症性肠病患者外周血白细胞介素12家族细胞因子的表达及临床意义[J].诊断学理论与实践，2015，14（2）：131-135.
[23] 唐文静，王婷婷，汪良芝.IL-35在炎症性肠病中的表达及临床价值[J].中国医药生物技术，2016，11（2）：142-144.
2019, Vol. 16 
京公网安备 11010502046598号